Compare Moody's Corporation (MCO) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Repligen Corporation Common Stock — how do they compare? Moody's Corporation trades at $462.77 (market cap $80.38B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Moody's Corporation is far larger — about 7.2× Repligen Corporation Common Stock's market cap, and Moody's Corporation pays a 0.89% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 133 Days and Repligen Corporation Common Stock for 0 Days on average.
| MCO | RGEN | |
|---|---|---|
Market Cap | $80.38B | $11.14B |
Volume | 628,586 | 1,259,263 |
Sector | Financials | Health |
52-Week High | $539.61 | $194.57 |
52-Week Low | $412.23 | $102.87 |
Typical Hold Time | 133 Days | 0 Days |
Enterprise Value | $86.40B | $11.02B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moody's Corporation (MCO) trades at $462.77, down 1.64% on the day, as the stock consolidates near key support. The company maintains strong fundamentals with revenue reaching $7.72B in 2025 and net income margin expanding to 34.25%. Recent earnings beats and a bullish technical signal underscore positive momentum, while analyst consensus remains favorable with a $536.40 price target. Strategic moves like the PhilRatings stake and Google Cloud partnership highlight growth initiatives in the Asia-Pacific region and financial services technology.
Outlook: Moody's exhibits robust profitability and strategic expansion, supporting a positive investment case. Risks include high valuation multiples (P/E 29.45) and sensitivity to credit cycle fluctuations. The stock offers growth potential but requires monitoring of debt levels and macroeconomic trends affecting its credit rating business.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
